You searched for viral vector - Page 15 of 53

Best in Biotech 29 Apr 2025

Six biotech companies leading the charge in hemophilia treatment

…solutions targeting neuroendocrine tumors and neuroblastoma. The company’s lead product for hemophilia A – ET3 – is an ex vivo hematopoietic stem cell (HSC) lentiviral vector (LV)-based gene therapy that…

April 29, 2025 - 10 minutesmins - By Willow Shah-Neville

News and Trends 28 Sep 2017

Oxford Spinout goes for $75M IPO on Nasdaq to Fund Gene Therapy Programs

…shepherding two candidates through Phase III, while Horama has staked out another rare disease and Eyevensys is testing a gene therapy that doesn’t use viral vectors. In the UK at…

September 28, 2017 - 2 minutesmins - By Evelyn Warner

Best in Biotech 17 Sep 2020

The Top 10 Biotech Companies Brewing at Oxford

…to clinical testing in Covid-19 patients. Oxford Biomedica Oxford Biomedica was set up in 1995 as a developer and provider of lentiviral vectors for gene and cell therapy. These vectors…

September 17, 2020 - 8 minutesmins - By Clara Rodríguez Fernández

Startup Scout 24 Jan 2020

This Company is Using Moths to Make Vaccines

…proteins in insect cells typically involves infecting the cells with a viral vector called baculovirus in large bioreactors. The downside of these industrial bioreactors is that they are expensive and…

January 24, 2020 - 4 minutesmins - By External Contributor

In Depth 30 Oct 2018

Shuttles, Bubbles and Ultrasound: Crossing the Blood–Brain Barrier

…are also being developed to deliver molecular payloads to the brain without disturbing normal function – including viral vectors, cell-based delivery, nanoparticle carriers, and molecular trojan horses, for example. But…

October 30, 2018 - 7 minutesmins - By External Contributor

News and Trends 4 Apr 2023

New research may lead to gene therapies for kidney disease

…gene delivery.” The solution, Onuchic and Caplan believe, may be to bring gene therapy for ADPKD down to a manageable scale. Gene therapy usually involves viral vectors, which means size…

April 4, 2023 - 5 minutesmins - By Jim Cornall

In Depth 20 Jan 2023

The future of single-cell microfluidics in cell engineering

…manufacturing process. In 2023, we will see continued application of the technology into manufacture and QC, particularly for ATMPs. The bottlenecks in viral vector production for cell therapy is a…

January 20, 2023 - 3 minutesmins - By External Contributor

News and Trends 11 Nov 2015

Oxford’s Nightstar Gene Therapy for Blindness in Men Shines with $35M Fundraiser

…the Choroideremia Research Foundation. Developed at Oxford’s Nuffield Lab of Ophthalmology in the UK by Robert MacLaren, Nightstar has a gene therapy which uses an adeno-associated retroviral vector (AAV). This…

November 11, 2015 - 3 minutesmins - By Dani Bancroft

Interview 31 Aug 2022

How CDMOs keep pace with trends in advanced therapies

…preclinical stage, and no products are commercially available yet. In the next decade, we expect exosomes to become a dominant non-viral vector modality, especially in therapeutic indications where targeted delivery…

August 31, 2022 - 8 minutesmins - By Jonathan Smith

researchers in lab; biotech collaboration

News and Trends 14 Jul 2022

GenScript ProBio enters strategic partnerships with two South Korean biotechs

…produce raw materials for subsequent pipelines. Using next-generation CAR-T technology, the ACT platform uses viral vectors to insert genes designed to target cancer antigens into the surrounding immune cells to…

July 14, 2022 - 3 minutesmins - By Omnia Ibrahim

News and Trends 29 Feb 2016

It’s Rare Disease Day 2016: Here are 7 Indications which Biotech is Fighting

…and uncertain. Theravectys (France) has an experimental treatment composed of two lentiviral vectors (THV02) to be used in a prime/boost regimen in ATL/L patients infected by the HTLV-1 virus, for…

February 29, 2016 - 6 minutesmins - By Dani Bancroft

News and Trends 22 Dec 2016

BMS Offers €850M for a British Oncolytic Virus better than CAR-T

…partner despite still being in the pre-clinical stage? PsiOxus’ platform, Tumor-Specific Immuno-Gene Therapy (T-Sign), uses a viral vector to deliver anti-cancer therapeutic transgenes to tumoral cells. In particular, NG-348 encodes…

December 22, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Search Results for: viral vector

Six biotech companies leading the charge in hemophilia treatment

Oxford Spinout goes for $75M IPO on Nasdaq to Fund Gene Therapy Programs

The Top 10 Biotech Companies Brewing at Oxford

This Company is Using Moths to Make Vaccines

Shuttles, Bubbles and Ultrasound: Crossing the Blood–Brain Barrier

New research may lead to gene therapies for kidney disease

The future of single-cell microfluidics in cell engineering

Oxford’s Nightstar Gene Therapy for Blindness in Men Shines with $35M Fundraiser

How CDMOs keep pace with trends in advanced therapies

GenScript ProBio enters strategic partnerships with two South Korean biotechs

It’s Rare Disease Day 2016: Here are 7 Indications which Biotech is Fighting

BMS Offers €850M for a British Oncolytic Virus better than CAR-T

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!